A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia

被引:242
作者
DiBonaventura, Marco [1 ]
Gabriel, Susan [2 ]
Dupclay, Leon [2 ]
Gupta, Shaloo [1 ]
Kim, Edward [2 ]
机构
[1] Kantar Hlth, Hlth Sci Practice, New York, NY USA
[2] Novartis Pharmaceut, Hlth Econ & Outcomes Res, E Hanover, NJ USA
关键词
HEALTH-CARE UTILIZATION; ANTIPSYCHOTIC-DRUGS; RISK-FACTORS; UNITED-STATES; COSTS; NONADHERENCE; PREVALENCE; BURDEN; AGREEMENT; VALIDITY;
D O I
10.1186/1471-244X-12-20
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Antipsychotic medications often have a variety of side effects, however, it is not well understood how the presence of specific side effects correlate with adherence in a real-world setting. The aim of the current study was to examine the relationship between these variables among community-dwelling patients with schizophrenia. Methods: Data were analyzed from a 2007-2008 nationwide survey of adults who self-reported a diagnosis of schizophrenia and were currently using an antipsychotic medication (N = 876). The presence of side effects was defined as those in which the patient reported they were at least "somewhat bothered". Adherence was defined as a score of zero on the Morisky Medication Adherence Scale. To assess the relationship between side effects and adherence, individual logistic regression models were fitted for each side effect controlling for patient characteristics. A single logistic regression model assessed the relationship between side effect clusters and adherence. The relationships between adherence and health resource use were also examined. Results: A majority of patients reported experiencing at least one side effect due to their medication (86.19%). Only 42.5% reported complete adherence. Most side effects were associated with a significantly reduced likelihood of adherence. When grouped as side effect clusters in a single model, extra pyramidal symptoms (EPS)/agitation (odds ratio (OR) = 0.57, p = 0.0007), sedation/cognition (OR = 0.70, p = 0.033), prolactin/endocrine (OR = 0.69, p = 0.0342), and metabolic side effects (OR = 0.64, p = 0.0079) were all significantly related with lower rates of adherence. Those who reported complete adherence to their medication were significantly less likely to report a hospitalization for a mental health reason (OR = 0.51, p = 0.0006), a hospitalization for a non-mental health reason (OR = 0.43, p = 0.0002), and an emergency room (ER) visit for a mental health reason (OR = 0.60, p = 0.008). Conclusions: Among patients with schizophrenia, medication side effects are highly prevalent and significantly associated with medication nonadherence. Nonadherence is significantly associated with increased healthcare resource use. Prevention, identification, and effective management of medication-induced side effects are important to maximize adherence and reduce health resource use in schizophrenia.
引用
收藏
页数:7
相关论文
共 30 条
[1]   A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia [J].
Ascher-Svanum, Haya ;
Zhu, Baojin ;
Faries, Douglas ;
Lacro, Jonathan P. ;
Dolder, Christian R. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (07) :1114-1123
[2]   Comparison of Patient and Clinician Perspectives in the Assessment of Antipsychotic Medication Adherence [J].
Barbui, Corrado ;
Kikkert, Martijn ;
Mazzi, Maria Angela ;
Becker, Thomas ;
Bindman, Jonathan ;
Schene, Aart ;
Nose, Michela ;
Helm, Hedda ;
Thornicroft, Graham ;
Tansella, Michele .
PSYCHOPATHOLOGY, 2009, 42 (05) :311-317
[3]  
Burton Simon C, 2005, J Psychiatr Pract, V11, P369, DOI 10.1097/00131746-200511000-00003
[4]   Quality of life in caregivers of patients with schizophrenia: A literature review [J].
Caqueo-Urizar, Alejandra ;
Gutierrez-Maldonado, Jose ;
Miranda-Castillo, Claudia .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2009, 7 :84
[5]   The association of well-being, productivity and resource use among community-dwelling patients with schizophrenia using atypical antipsychotics [J].
DiBonaventura, Marco Dacosta ;
Panish, Jessica ;
Kenworthy, Debbie ;
Wagner, Jan-Samuel ;
Dirani, Riad .
JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2010, 1 (04) :181-187
[6]   Determinants of medication compliance in schizophrenia: Empirical and clinical findings [J].
Fenton, WS ;
Blyler, CR ;
Heinssen, RK .
SCHIZOPHRENIA BULLETIN, 1997, 23 (04) :637-651
[7]   Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder [J].
Goff, Donald C. ;
Hill, Michele ;
Freudenreich, Oliver .
JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 :20-26
[8]   Prevalence and incidence studies of schizophrenic disorders: A systematic review of the literature [J].
Goldner, EM ;
Hsu, L ;
Waraich, P ;
Somers, JM .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (09) :833-843
[9]   The cost diary:: a method to measure direct and indirect costs in cost-effectiveness research [J].
Goossens, MEJB ;
Rutten-van Mölken, MPH ;
Vlaeyen, JWS ;
van der Linden, SMJP .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (07) :688-695
[10]   The SOHO (schizophrenia outpatient health outcome) study - Implications for the treatment of schizophrenia [J].
Haro, Josep Maria ;
Salvador-Carulla, Luis .
CNS DRUGS, 2006, 20 (04) :293-301